



PATIENT NAME: VAIBHAV SHARMA

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

REF. DOCTOR: SELF

ACCESSION NO: 0006WK005524 AGE/SEX : 36 Years PATIENT ID DRAWN :06/11/2023 09:39:00 : FH.12805743

CLIENT PATIENT ID: UID:12805743 RECEIVED: 06/11/2023 15:31:21

ABHA NO

REPORTED :06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

:	HAEMATOLOGY - CBC					
CBC-5, EDTA WHOLE BLOOD						
BLOOD COUNTS, EDTA WHOLE BLOOD						
HEMOGLOBIN (HB) METHOD: SLS- HEMOGLOBIN DETECTION METHOD	15.5	13.0 - 17.0	g/dL			
RED BLOOD CELL (RBC) COUNT METHOD: HYDRODYNAMIC FOCUSING	5.10	4.5 - 5.5	mil/µL			
WHITE BLOOD CELL (WBC) COUNT METHOD: FLOWCYTOMETRY	5.47	4.0 - 10.0	thou/µL			
PLATELET COUNT METHOD: HYDRO DYNAMIC FOCUSING METHOD / MICROSCOPY	219	150 - 410	thou/µL			
RBC AND PLATELET INDICES						
HEMATOCRIT (PCV) METHOD: HYDRODYNAMIC FOCUSING	48.9	40.0 - 50.0	%			
MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER	95.9	83.0 - 101.0	fL			
MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER	30.4	27.0 - 32.0	pg			
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION(MCHC) METHOD: CALCULATED PARAMETER	31.7	31.5 - 34.5	g/dL			
RED CELL DISTRIBUTION WIDTH (RDW) METHOD: CALCULATED PARAMETER	15.4 High	11.6 - 14.0	%			
MENTZER INDEX	18.8					
METHOD: CALCULATED PARAMETER MEAN PLATELET VOLUME (MPV) METHOD: CALCULATED PARAMETER	12.2 High	6.8 - 10.9	fL			

WBC DIFFERENTIAL COUNT

Dr. Shafira Garg (MD, Pathology) Attending Consultant,47150

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Ritu Pantay

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159

Meenahahi Malhotra



Page 1 Of 14



View Report



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006WK005524 PATIENT ID : FH.12805743

CLIENT PATIENT ID: UID:12805743 ABHA NO

AGE/SEX :36 Years :06/11/2023 09:39:00 DRAWN RECEIVED: 06/11/2023 15:31:21 REPORTED :06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

BILLINO-10021230PCR018563			
Test Report Status <u>Final</u>	Results	Biological Reference	e Interval Units
NEUTROPHILS	43	40.0 - 80.0	%
METHOD: FLOW CYTOMETRY+LEISHMAIN STAIN+MICROSCOP	Υ		
LYMPHOCYTES	48 High	20.0 - 40.0	%
METHOD: FLOW CYTOMETRY+LEISHMAIN STAIN+MICROSCOP	Υ		
MONOCYTES	7	2.0 - 10.0	%
METHOD: FLOW CYTOMETRY+LEISHMAIN STAIN+MICROSCOP			
EOSINOPHILS	2	1 - 6	%
METHOD: FLOW CYTOMETRY+LEISHMAIN STAIN+MICROSCOP			
BASOPHILS	00	0 - 2	%
METHOD: FLOW CYTOMETRY+LEISHMAIN STAIN+MICROSCOP			
ABSOLUTE NEUTROPHIL COUNT	2.35	2.0 - 7.0	thou/µL
METHOD : CALCULATED PARAMETER	2.62	10.00	#h/I
ABSOLUTE LYMPHOCYTE COUNT	2.63	1.0 - 3.0	thou/µL
METHOD : CALCULATED PARAMETER	0.20	0.2 1.0	+h o.u /u.l
ABSOLUTE MONOCYTE COUNT	0.38	0.2 - 1.0	thou/μL
METHOD : CALCULATED PARAMETER ABSOLUTE EOSINOPHIL COUNT	0.11	0.02 - 0.50	thou/µL
METHOD : CALCULATED PARAMETER	0.11	0.02 - 0.30	ι Ιου, μΕ
NEUTROPHIL LYMPHOCYTE RATIO (NLR)	0.9		
METHOD : CALCULATED PARAMETER	0.5		

Interpretation(s)
RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR <

3.3, COVID-19 patients tend to show mild disease. (Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Ritu Pantay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Meenahsh: Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159





Page 2 Of 14

View Report



CLINICAL LABORATORY

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







REF. DOCTOR: SELF PATIENT NAME: VAIBHAV SHARMA

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006WK005524 PATIENT ID : FH.12805743

CLIENT PATIENT ID: UID:12805743

ABHA NO

AGE/SEX : 36 Years :06/11/2023 09:39:00 DRAWN RECEIVED: 06/11/2023 15:31:21 REPORTED: 06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

HAEMATOLOGY

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

17 High 0 - 14mm at 1 hr E.S.R

METHOD: WESTERGREN METHOD

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C Non-diabetic: < 5.7 %

> Pre-diabetics: 5.7 - 6.4 Diabetics: > or = 6.5Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: HPLC

mg/dL 108.3 ESTIMATED AVERAGE GLUCOSE(EAG) < 116.0

METHOD: CALCULATED PARAMETER

Interpretation(s)

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-TEST DESCRIPTION :-

Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall (sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy, Estrogen medication, Aging.

Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias, Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc.), Hypercholesterolemia
False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs(Quinine,

salicylates)

Ritu Pantay

Meenahah Malhotra

Page 3 Of 14

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159





View Report



CLINICAL LABORATORY

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704

Email: srl.mohali@fortishealthcare.com





AGE/SEX

DRAWN



REF. DOCTOR: SELF PATIENT NAME: VAIBHAV SHARMA

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006WK005524 PATIENT ID : FH.12805743

CLIENT PATIENT ID: UID:12805743 ABHA NO

RECEIVED: 06/11/2023 15:31:21

: 36 Years

REPORTED: 06/11/2023 17:49:25

:06/11/2023 09:39:00

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

- 1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis, 10th edition.

 GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:
- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2. Diagnosing diabetes.

3. Identifying patients at increased risk for diabetes (prediabetes).
The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for well-controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1. eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

- eAG gives an evaluation of blood glucose levels for the last couple of months.
 eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c 46.7

HbA1c Estimation can get affected due to :

- 1. Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss, hemolytic anemia) will falsely lower HbA1c test results. Fructosamine is recommended in these patients which indicates diabetes control over 15 days. 2. Vitamin C & E are reported to falsely lower test results. (possibly by inhibiting glycation of hemoglobin.
- 3. Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism,chronic ingestion of salicylates & opiates
- addiction are reported to interfere with some assay methods, falsely increasing results.

 4. Interference of hemoglobinopathies in HbA1c estimation is seen in
- a) Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c.
- b) Heterozygous state detected (D10 is corrected for HbS & HbC trait.)
- c) HDF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy

Ritu Pankay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159

Meenahsh: Malhotra





Page 4 Of 14

View Report



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: srl.mohali@fortishealthcare.com

Dr. Shafira Garg (MD, Pathology)

Attending Consultant, 47150







PATIENT NAME: VAIBHAV SHARMA

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

REF. DOCTOR: SELF

ACCESSION NO: 0006WK005524 PATIENT ID : FH.12805743

CLIENT PATIENT ID: UID:12805743 ABHA NO

AGE/SEX : 36 Years DRAWN :06/11/2023 09:39:00 RECEIVED: 06/11/2023 15:31:21 REPORTED :06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

	BIOCHEMISTRY		
LIVER FUNCTION PROFILE, SERUM			
BILIRUBIN, TOTAL	1.11	UPTO 1.2	mg/dL
METHOD : DIAZONIUM ION, BLANKED (ROCHE)	0.20	0.00	
BILIRUBIN, DIRECT METHOD: DIAZOTIZATION	0.30	0.00 - 0.30	mg/dL
BILIRUBIN, INDIRECT	0.81 High	0.00 - 0.60	mg/dL
METHOD : CALCULATED PARAMETER	•	0.00	3,
TOTAL PROTEIN	7.9	6.6 - 8.7	g/dL
METHOD: BIURET			4.0
ALBUMIN	4.8	3.97 - 4.94	g/dL
METHOD: BROMOCRESOL GREEN GLOBULIN	3.1	2.0 - 4.0	g/dL
GLOBOLIN	5.1	Neonates -	3/ 4-
		Pre Mature:	
		0.29 - 1.04	
METHOD : CALCULATED PARAMETER ALBUMIN/GLOBULIN RATTO	1.6	1.0 - 2.0	RATIO
METHOD : CALCULATED PARAMETER	1.0	1.0 2.0	101120
ASPARTATE AMINOTRANSFERASE(AST/SGOT)	41 High	0 - 40	U/L
ALANINE AMINOTRANSFERASE (ALT/SGPT)	69 High	0 - 41	U/L
METHOD: UV WITHOUT PYRIDOXAL-5 PHOSPHATE			
ALKALINE PHOSPHATASE	98	40 - 129	U/L
METHOD: PNPP - AMP BUFFER	22	0 61	11/1
GAMMA GLUTAMYL TRANSFERASE (GGT) METHOD: GAMMA GLUTAMYLCARBOXY 4NITROANILIDE	22	8 - 61	U/L
LACTATE DEHYDROGENASE	207	135 - 225	U/L
METHOD: LACTATE -PYRUVATE UV		133 223	-,

GLUCOSE FASTING, FLUORIDE PLASMA

FBS (FASTING BLOOD SUGAR) 84 74 - 106 mg/dL

METHOD: HEXOKINASE

Meenahshi Malhotra

Ritu Pantay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Page 5 Of 14







View Report



CLINICAL LABORATORY

Dr. Meenakshi Malhotra, MD

Senior Consultant, 48159

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006WK005524**PATIENT ID: FH.12805743

CLIENT PATIENT ID: UID:12805743

ABHA NO :

AGE/SEX :36 Years Male
DRAWN :06/11/2023 09:39:00
RECEIVED :06/11/2023 15:31:21
REPORTED :06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

Test Report Status Final Results Biological Reference Interval Units

BLOOD UREA NITROGEN (BUN), SERUM

BLOOD UREA NITROGEN 11 6 - 20 mg/dL

METHOD: UREASE - UV

URIC ACID, SERUM

URIC ACID 6.6 3.4 - 7.0 mg/dL

METHOD: URICASE, COLORIMETRIC

CREATININE EGFR

CREATININE 1.00 0.70 - 1.20 mg/dL

METHOD: ALKALINE PICRATE-KINETIC

AGE 36 years

GLOMERULAR FILTRATION RATE (MALE) 100 GFR of +90

normal or minimal kidney damage with normal GFR

89-60

mild decrease

59-30

moderate decrease

29-15

severe decrease < 15 kidney failure

(units: mL/min/1.73mSq.)

Interpretation(s)

Meenahshi Malhotra

Ritu Pantay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897 Ms. Hardeep Kaur, M.Sc. Biochemistry Page 6 Of 14





View Details

View Report



Dr. Meenakshi Malhotra, MD

Senior Consultant, 48159

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







REF. DOCTOR: SELF PATIENT NAME: VAIBHAV SHARMA

FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALT 160062 7087030817

ACCESSION NO: 0006WK005524

: FH.12805743 CLIENT PATIENT ID: UID:12805743

ABHA NO

PATIENT ID

AGE/SEX : 36 Years :06/11/2023 09:39:00 DRAWN

RECEIVED: 06/11/2023 15:31:21 REPORTED :06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

Test Report Status Results Biological Reference Interval Units <u>Final</u>

GLUCOSE POST-PRANDIAL, PLASMA

PPBS(POST PRANDIAL BLOOD SUGAR) 105 Non-Diabetes mg/dL 70 - 140

METHOD: HEXOKINASE

Interpretation(s)

LIVER FUNCTION PROFILE, SERUM-

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. **Elevated levels** results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia, pancreatitis, hemochromatosis. AST levels may also increase after a heart attack or strenuous activity. ALT test measures the amount of this enzyme in the blood. ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas. It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health. AST levels increase during acute hepatitis, sometimes due to a viral infection, ischemia to the liver, chronic hepatitis, obstruction of bile ducts, cirrhosis.

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Pagets disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilsons disease. **GGT** is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain

and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc.

Total Protein also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstroms disease.Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome, Protein-losing enteropathy etc.

Albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by:Liver disease like cirrhosis of the liver, nephrotic syndrome,protein-losing enteropathy,Burns,hemodilution,increased vascular permeability or decreased lymphatic clearance,malnutrition and wasting etc GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

Increased in:Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Decreased in:Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency,hypopituitarism,diffuse liver disease,

malignancy(adrenocortical,stomach,fibrosarcoma),infant of a diabetic mother,enzyme deficiency diseases(e.g.galactosemia),Drugs-insulin,ethanol,propranolol;sulfonylureas,tolbutamide,and other oral hypoglycemic agents.

NOTE: While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within

individuals.Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc

Meenahahi Malhotra

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Ritu Pantay

Ms. Hardeep Kaur, M.Sc. **Biochemistry**



Page 7 Of 14

View Report



CLINICAL LABORATORY

Dr. Meenakshi Malhotra, MD

Senior Consultant, 48159

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Mohali, 160062 Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006WK005524 AGE/SEX

PATIENT ID : FH.12805743

CLIENT PATIENT ID: UID:12805743 ABHA NO

:06/11/2023 09:39:00 DRAWN RECEIVED: 06/11/2023 15:31:21 REPORTED :06/11/2023 17:49:25

:36 Years

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

Biological Reference Interval Test Report Status Results Units <u>Final</u>

BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism) Causes of decreased level include Liver disease, SIADH.

URIC ACID, SERUM-**Causes of Increased levels:**-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome **Causes of decreased levels**-Low Zinc intake,OCP,Multiple Sclerosis GLUCOSE POST-PRANDIAL, PLASMA-Spectrophotometry Hexokinase

Meenahshi Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159

Ritu Pantay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry**





Page 8 Of 14





Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -L85110DL1996PLC076704

Email: srl.mohali@fortishealthcare.com







FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006WK005524 PATIENT ID : FH.12805743

CLIENT PATIENT ID: UID:12805743

ABHA NO

AGE/SEX : 36 Years Male DRAWN :06/11/2023 09:39:00 RECEIVED: 06/11/2023 15:31:21 REPORTED :06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

Test Report Status Results **Biological Reference Interval Final**

BIOCHEMISTRY - LIPID

	SERUN	

CHOLESTEROL, TOTAL 223 High < 200 Desirable mg/dL

200 - 239 Borderline High

>/= 240 High

METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

mg/dL 178 High < 150 Normal TRIGLYCERIDES

150 - 199 Borderline High

200 - 499 High >/= 500 Very High

METHOD: ENZYMATIC ASSAY

HDL CHOLESTEROL 47 < 40 Low mg/dL

>/=60 High

METHOD: DIRECT MEASURE - PEG 156 High

mg/dL LDL CHOLESTEROL, DIRECT < 100 Optimal

100 - 129 Near or above

optimal

130 - 160 Borderline High

161 - 189 High >/= 190 Very High

METHOD: CHOLESTEROL OXIDASE, ESTERASE, PEROXIDASE

176 High mg/dL NON HDL CHOLESTEROL Desirable: Less than 130

Above Desirable: 130 - 159 Borderline High: 160 - 189

High: 190 - 219 Very high: > or = 220

VERY LOW DENSITY LIPOPROTEIN 35.6 High Desirable value :

10 - 35

METHOD: CALCULATED PARAMETER

CHOL/HDL RATIO 4.7 High 3.3-4.4 Low Risk

4.5-7.0 Average Risk 7.1-11.0 Moderate Risk

> 11.0 High Risk

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenahsh Malhot

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159





Page 9 Of 14





Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

L85110DL1996PLC076704 Email: srl.mohali@fortishealthcare.com

mg/dL

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006WK005524 PATIENT ID : FH.12805743

CLIENT PATIENT ID: UID:12805743

ABHA NO

AGE/SEX : 36 Years DRAWN :06/11/2023 09:39:00 RECEIVED: 06/11/2023 15:31:21

REPORTED :06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406 CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

METHOD: CALCULATED PARAMETER

Test Report Status Results **Biological Reference Interval** Units <u>Final</u>

3.3 High LDL/HDL RATIO 0.5 - 3.0 Desirable/Low Risk

3.1 - 6.0 Borderline/Moderate

Risk

>6.0 High Risk

Interpretation(s)

Ritu Pantay

Dr. Ritu Pankaj, MD, PDCC Senior Consultant, 30897

Ms. Hardeep Kaur, M.Sc. **Biochemistry**

Meenahshi Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159





Page 10 Of 14





Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704 Email: srl.mohali@fortishealthcare.com



CLINICAL LABORATORY





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006WK005524 PATIENT ID : FH.12805743

CLIENT PATIENT ID: UID:12805743 ABHA NO

AGE/SEX : 36 Years :06/11/2023 09:39:00 DRAWN RECEIVED: 06/11/2023 15:31:21 REPORTED :06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

Results **Test Report Status Biological Reference Interval** Units <u>Final</u>

CLINICAL PATH - URINALYSIS

URINALYSIS

PHYSICAL EXAMINATION, URINE

COLOR YELLOW

METHOD: MANUAL EXAMINATION

APPEARANCE CLEAR

METHOD: MANUAL EXAMINATION

CHEMICAL EXAMINATION, URINE

4.7 - 7.55.5 PH

METHOD: DOUBLE INDICATOR PRINCIPLE

SPECIFIC GRAVITY >=1.030 1.003 - 1.035

METHOD: REFLECTANCE PHOTOMETRY (IONIC CONCENTRATION)

NOT DETECTED NOT DETECTED

METHOD: REFLECTION PHOTOMETRY (PROTEIN ERROR INDICATOR)

GLUCOSE NOT DETECTED NOT DETECTED

METHOD: REFLECTANCE PHOTOMETRY (GLUCOSE OXIDASE METHOD)

NOT DETECTED **KFTONES** NOT DETECTED

METHOD: REFLECTION PHOTOMETRY (NITROPRUSSIDE)

DETECTED (+) BLOOD NOT DETECTED

METHOD: REFLECTANCE PHOTOMETRY (BENZIDINE REACTION)

NOT DETECTED NOT DETECTED BILIRUBIN

METHOD: REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION)

UROBILINOGEN NORMAL **NORMAL**

METHOD: REFLECTANCE PHOTOMETRY (EHRLICH'S REACTION)

NOT DETECTED NOT DETECTED NITRITE

METHOD: REFLECTANCE SPECTROPHOTOMETRY (DIAZO REACTION)

MICROSCOPIC EXAMINATION, URINE

Dr. Shafira Garg (MD, Pathology) Attending Consultant, 47150

Dr. Meenakshi Malhotra, MD

Meenahsh Malhot

Senior Consultant, 48159





Page 11 Of 14



Dr. Irneet Mundi, MD

Associate Consultant, 34080

Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006WK005524 PATIENT ID : FH.12805743

CLIENT PATIENT ID: UID:12805743

ABHA NO

AGE/SEX : 36 Years DRAWN :06/11/2023 09:39:00 RECEIVED : 06/11/2023 15:31:21

REPORTED :06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

DILLINO 100212301 CR01	10303			
Test Report Status	<u>Final</u>	Results	Biological Reference I	nterval Units
RED BLOOD CELLS		2 - 3	NOT DETECTED	/HPF
PUS CELL (WBC'S)		NOT DETECTED	0-5	/HPF
EPITHELIAL CELLS		NOT DETECTED	0-5	/HPF
CASTS		NOT DETECTED		
CRYSTALS		NOT DETECTED		
BACTERIA METHOD: REFLECTANCE SPEC	TROPHOTOMETRY	NOT DETECTED	NOT DETECTED	
YEAST		NOT DETECTED	NOT DETECTED	

Interpretation(s)

Dr. Irneet Mundi, MD Associate Consultant, 34080

Dr. Shafira Garg (MD, Pathology) Attending Consultant,47150

Meenahahi Malhotra

Dr. Meenakshi Malhotra, MD Senior Consultant, 48159





Page 12 Of 14

View Report



CLINICAL LABORATORY Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

L85110DL1996PLC076704



Punjab, India Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

Email: srl.mohali@fortishealthcare.com





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817

ACCESSION NO: 0006WK005524 PATIENT ID : FH.12805743

CLIENT PATIENT ID: UID:12805743

ABHA NO

AGE/SEX : 36 Years :06/11/2023 09:39:00 DRAWN RECEIVED: 06/11/2023 15:31:21 REPORTED :06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

Results **Biological Reference Interval Test Report Status** <u>Final</u>

CLINICAL PATH - STOOL ANALYSIS

STOOL: OVA & PARASITE

PHYSICAL EXAMINATION, STOOL

COLOUR **BROWN**

CONSISTENCY WELL FORMED

MUCUS NOT DETECTED **ABSENT**

METHOD: MICROSCOPIC EXAMINATION

VISIBLE BLOOD **ABSENT ABSENT**

NOT DETECTED ADULT PARASITE

METHOD: MANUAL

MICROSCOPIC EXAMINATION, STOOL

/hpf **PUS CELLS** NOT DETECTED /HPF RED BLOOD CELLS NOT DETECTED NOT DETECTED

NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED NOT DETECTED **CYSTS**

METHOD: MICROSCOPIC EXAMINATION

OVA

METHOD: MICROSCOPIC EXAMINATION

NOT DETECTED **NOT DETECTED** I ARVAF

TROPHOZOITES NOT DETECTED NOT DETECTED

METHOD: MICROSCOPIC EXAMINATION

METHOD: MICROSCOPIC EXAMINATION

Interpretation(s)

Dr. Anita Sharma, MD Associate Director, 27672





Page 13 Of 14



Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii,

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -

L85110DL1996PLC076704



CLINICAL LABORATORY

Mohali, 160062

Email: srl.mohali@fortishealthcare.com





FORTIS MOHALI-CHC -SPLZD FORTIS HOSPITAL # MOHALI,

MOHALI 160062 7087030817 ACCESSION NO: **0006WK005524**PATIENT ID : FH.12805743

CLIENT PATIENT ID: UID:12805743

ABHA NO :

AGE/SEX :36 Years Male
DRAWN :06/11/2023 09:39:00
RECEIVED :06/11/2023 15:31:21
REPORTED :06/11/2023 17:49:25

CLINICAL INFORMATION:

UID:12805743 REQNO-1603406

CORP-OPD

BILLNO-10021230PCR018563 BILLNO-10021230PCR018563

Test Report Status	<u>Final</u>	Results	Biological Reference Interval	Units
---------------------------	--------------	---------	--------------------------------------	-------

	SPECIALISED CHEMISTRY - H	ORMONE	
THYROID PANEL, SERUM			
Т3	138.8	80.00 - 200.00	ng/dL
METHOD : SANDWICH (ECLIA)			
T4	10.17	5.10 - 14.10	μg/dL
METHOD : SANDWICH (ECLIA)			
TSH (ULTRASENSITIVE)	1.690	0.270 - 4.200	μIU/mL
METHOD: SANDWICH (ECLIA)			

Interpretation(s)

End Of Report
Please visit www.agilusdiagnostics.com for related Test Information for this accession

Meenahshi Malhotra

Ritu Pantaj

Dr. Meenakshi Malhotra, MD Senior Consultant,48159 Dr. Ritu Pankaj, MD, PDCC Senior Consultant,30897





Page 14 Of 14

View Details

View Report



CLINICAL LABORATORY
Fortis Heart Institute & Multispeciality Hospital, Sector 62, Phase Viii, Mohali, 160062

Punjab, India

Tel: 0172-469-2222 Extn. 6726, 6727), 0172-469-2221 - CIN -



Fortis MEDCENTRE

CHANDIGARH
(A unit of Fortis Hospital Mohali)
SCO 11, Sector 11-D, Chandigarh - 160011

Name		Mr. Vai 61	halv	Sh	a s	119
UHID	:_	12805743	Date : _	.6	111	2023
Age	:_	36	Gender	H	el	

	Profile
the state of the s	
Height (cm): 172cm	Waist Circumference (cm): 32 inches
Weight (Kg.): 8018	Body Mass Index: 27 0 Kg/HL
Occupation: Job	Marital Status Single Married
Vit	al Signs 5102 97%
Pulse Rate (/min): 66 mls	Respiratory Rate (/min): 2 m
Blood Pressure (mmHg): 100/20mm Hs	Temperature (if febrile): afeling
Past	t History
Hypertension:	Diabetes:
Heart disease :	Dyslipidemia :
Asthma:	Tuberculosis :
☐ Allergies : ☐ Others :	
Others:	Women 1
Others:	T
Others:	
Others: For LMP:	Last Pap smear done in
Others: For LMP: Menopause Yes No Consent for X-ray & Mammography	Last Pap smear done in
Others: For LMP: Menopause Yes No Consent for X-ray & Mammography	Last Pap smear done in Last Mammography done in
Others: For LMP: Menopause Yes No Consent for X-ray & Mammography	Last Pap smear done in Last Mammography done in
Others: For LMP: Menopause Yes No Consent for X-ray & Mammography	Last Pap smear done in Last Mammography done in
Others: For LMP: Menopause Yes No Consent for X-ray & Mammography	Last Pap smear done in Last Mammography done in

Signature, Name and Emp. ID of the Nurse : _____

Fortis MEDCENTRE

CHANDIGARH (A unit of Fortis Hospital Mohali) SCO 11, Sector 11-D, Chandigarh - 160011

Name		Mr. Vaibh	au Sharma
UHID		-12805743	Date: _6/11/23
Age	:_	36	Gender: Helf

8477043210

Internal Medicine Consultation

-		of the same	and the	
Re	AVA	nt l	Hist	torv:

Diagnosis:

Boils on scolb.

Examination Findings:

Advice / Treatment Plan:

Investigations:

Dr. VIJAY KUMAR HARJATI
MBBS.MD (Internal Medicine)
Consultant Internal Medicine
Reg. No.PMC 19814
Mobile:0 98142 03424
Fortis MEDCENTRE (A unit of Fortis Hospital, No.C.O. 11, Sector 11-0, Chandigarin-160011 (1)
Phone No.0172-5061222, S055441

Fortis MEDCENTRE

CHANDIGARH

(A unit of Fortis Hospital Mohali)

Chandinarh - 16001 SCO 11, Sector 11-D, Chandigarh - 160011

Signature and stamp of the Ophthalmologist:

Name		M.	Vaibb	· S	ha	AM	2
UHID	:_	128	05743	Date :	6	11	123
Age	:_	36		_ Gender:	Ha	le	

Ophthalmology Consultation	
History:	
Examination findings: Visual acuity R Visual acuity with glasses L	Colour Vision R
	N.
Slit Lamp Examination	LE //
Fundus Examination	
RE O	LE
Diagnosis:	
Treatment"	
Spectacle prescription:	
Right eye	Left eye
SPH CYL AXIS VA	SPH CYL AXIS VA
Distance	Distance ·
Near	Near

--/-- mmHg 58 bpm 1/1 2x5x6_25_R1 Unconfirmed Room: 50 Hz 0.56-40 Hz Location: Order Number: Visit: Medication 1: Medication 2: Medication 3: Indication: ADS 25 mm/s 10 mm/mV 7 Sinus bradycardia Otherwise normal ECG 06.11.2023 10:06:53 Fortis Med Centre sector 11 Chandgarh 92 ms 1040 / 1034 ms 42 / 54 / 39 degrees 125LTM v241 70 ms 380 / 373 ms 162 ms 1.1 Technician: Ordering Ph: Referring Ph: Attending Ph: QRS: QT/QTcBaz: PR: P: RR/PP: P/QRS/T: GE MAC2000 Male Sharma, Vaibhav ID: 12805743 **aVR** aVL **AVE** E



Fortis Medcentre

SCO-11, Sector-11-D,

Chandigarh - 160 011 (India)

Telephone 0172 506 1222 / 505 5441 0172-5055440 Fax

contactus.fmc@fortishealthcare.com

E-mail Website www.fortishealthcare.com

DEPARTMENT OF CARDIOLOGY ECHOCARDIOGRAPHY LABORATORY Phone 0172-5061222; Ext. 6422

Dated:6 November 2023

Name:

MR VAIBHAV SHARMA

Age: 36

Sex: M

FHL No:

12805743

Lab No:

Clinical Diagnosis:

R/O CAD

Ref By:

FMC

MEASUREMENTS

Aortic Root Diameter

Left Atrial dimension 2.8 cm

2.8

cm

cm

Aortic Valve Opening

cm

Right Ventricular dimension

1.2 cm

Left Ventricular ED dimension

3.9

Left Ventricular ES dimension cm

2.6

Interventricular Septal thickness

ED: 0.9

cm

ES:

1.5 cm

Left Ventricular PW thickness

1.0 ED: cm ES: 1.5 cm

INDICES OF LEFT VENTRICULAR FUNCTION:

LV Ejection Fraction

% 62

IMAGING:

M mode examination revealed normal movement of both Mitral leaflets during diastole. No SAM or Mitral valve prolapse is seen. Aortic root is normal in size. Dimensions of left atrium and left ventricle are normal

2-D imaging in PLAX. SAX and apical views revealed normal sized left ventricle. Movement of anterior wall, septum, apex, inferior wall, posterior and lateral walls is normal. Mitral valve opening is normal. No evidence of Mitral valve prolapse is seen. Aortic valve has three cusps and its opening is not restricted. Pulmonary valve is normal. Interatrial and interventricular septa are intact. No intracardiac mass or thrombus is seen. No pericardial pathology is observed.

A unit of FORTIS HOSPITAL MOHALI

Sector 62, Phase - VIII, Mohali - 160062, Punjab (India); Tel: +91 172 469 2222, 469 2250 Fax: +91 172 469 2221

Page 1 of 2





Fortis Medcentre

SCO-11, Sector-11-D,

Chandigarh - 160 011 (India)

Telephone : 0172 506 1222 / 505 5441 Fax

: 0172-5055440

E-mail

: contactus.fmc@fortishealthcare.com www.fortishealthcare.com

Website

DEPARTMENT OF CARDIOLOGY ECHOCARDIOGRAPHY LABORATORY Phone 0172-5061222; Ext. 6422

DOPPLER: PULSE WAVE; CONTINUOUS WAVE & COLOR FLOW MAPPING

Mitral Valve

84 : E=

A = 59

cm/sec; E > A; No MR

E wave Deceleration Time = 183 msec

Aortic Valve

: 107 cm/sec TRIVIAL AR

Tricuspid Valve

No TR; RVSP = + RAP mmHg

Pulmonary Valve

: 100 cm/sec

FINAL DIAGNOSIS

- NO REGIONAL WALL MOTION ABNORMALITY OF LEFT VENTRICLE
- LEFT VENTRICULAR NORMAL SYSTOLIC FUNCTION (LVEF 62%)
- TRIVIAL AR

Collanne Dr. MUKTI SHARMA MD, DNB, FIAP, FCSI

Sr. Consultant Fortis MEDCENTRE





CHANDIGARH

Fortis Medcentre

SCO-11, Sector-11-D, Chandigarh - 160 011 (India)

Telephone : 0172 506 1222 / 505 5441 Fax : 0172-5055440

: contactus.fmc@fortishealthcare.com

: www.fortishealthcare.com Website

NAME: MR. VAIBHAV SHARMA

AGE AND SEX: 36Y/M UHID NO: 12805743 DATE:06/11/2023

CHEST- PA

Both the domes of diaphragm are normal.

Both costophrenic angles are normal.

Both lung fields are clear.

Cardiac size and silhouette are normal.

Both hila and mediastinum are normal.


Bony cage and soft tissues are normal.

IMPRESSION: NORMAL STUDY.

Please correlate clinically and with other relevant investigations.

Dr. ADITI PANWAR PMC-41230 Consultant Radiologist







CHANDIGARH

Fortis Medcentre

SCO-11, Sector-11-D, Chandigarh - 160 011 (India)

Telephone : 0172 506 1222 / 505 5441 Fax : 0172-5055440

E-mail : contactus.fmc@fortishealthcare.com : www.fortishealthcare.com

Website

NAME: MR. VAIBHAV SHARMA

AGE AND SEX: 36Y/M UHID NO: 12805743 DATE:06/11/2023

ROI: WHOLE ABDOMEN

Liver is normal in size, outline and echogenicity. No focal lesion seen. IHBR's are not dilated. Portal vein and hepatic veins are normal.

Gall bladder is normally distended with anechoic lumen. Wall thickness is normal. No calculus / focal lesion seen. No pericholecystic fluid / collection seen. CBD is normal.

Pancreas is visualized in region of head and proximal body and is normal in size, shape, outline and echotexture. No focal lesion seen. Distal body and tail are obscured by bowel gases.

Spleen is mildly prominent (11.3cm) in size with normal outline and echotexture. No focal lesion seen.

Right kidney is normal in size, outline and echogenicity. Cortico-medullary differentiation is maintained. No hydronephrosis / calculus is seen.

Left kidney is normal in size, outline and echogenicity. Cortico-medullary differentiation is maintained. No hydronephrosis / calculus is seen. A parapelvic cyst of size 8mm is seen.

Retroperitoneum is normal.

The urinary bladder is fully distended and is normal in outline and wall thickness. No calculi or growth seen.

Prostate is normal in size and shows normal outline and echo pattern. No focal lesion seen.

No free fluid is seen.

Opinion: Mildly Prominent Spleen. Left Renal Cyst.

Suggested clinical correlation.

Dr. ADITI PANWAR PMC - 41230 Consultant Radiologist

A unit of FORTIS HOSPITAL MOHALI

Sector 62, Phase - VIII, Mohali - 160062, Punjab (India); Tel: +91 172 469 2222, 469 2250 Fax: +91 172 469 2221



VAIBHAV SHARMA 36/M

Patient ID: 12805743

Accession #:

Study Date: 06/11/2023

Alt ID:

DOB:

Age:

Gender: M Ht:

Wt:

BSA:

Institution: Fortis MEDCENTRE, Chandigarh Referring Physician:

Physician of Record:

Comments:

Performed By:

lmages



gnature

ignature: ame(Print):

Date: